NOTE TO READERS: When this project lost substantial funding at the end of 2018, I lost the ability to continue publishing criteria-driven news story reviews and PR news release reviews - once the bread-and-butter of the site going back to 2006. The 3,200 archived reviews, while still educational, are getting old and difficult for me to technically maintain on the back end of the website. So I am announcing that I plan to remove these reviews from the site by April 1, 2021. The blog and the toolkit - two of the most popular features on the site - will remain. If you wish to peruse the reviews before they disappear, please do so by the end of March 2021. After that date you may still be able to access them via the Internet Archive Wayback Machine - https://archive.org/web/.

Tags: monoclonal antibody drugs

4/3/2017

Lack of independent sources weaken NBC’s look at pricey eczema drug

11/21/2016

Bloomberg’s conflicted sources ‘love’ new cholesterol drugs — readers need to know about financial relationships with pharma

10/20/2016

Potential conflicts of interest abound in HealthDay’s look at Lemtrada for early stages of MS

5/24/2016

Except for presidential anecdote, NBC story on new melanoma drug was well-balanced

Story Reviews

Systematic, Criteria-Driven

@HealthNewsRevu

Retweet on TwitterHealthNewsReview.org Retweeted
AKECasselsAlan Cassels@AKECassels·

Puleeeeease... this 'game changer' weight loss drug causes more nausea and vomiting than a placebo. Some game, some change. My friend Gary would spank you for using the eighth word medical reporters should never, ever use. @garyschwitzer @thackerpd
https://www.healthnewsreview.org/toolkit/just-journalists-writing-tips-case-studies/7-words-and-more-you-shouldnt-use-in-medical-news/ https://twitter.com/OttawaCitizen/status/1361426796126830597

Reply on Twitter 1361431489326407680Retweet on Twitter 13614314893264076806Like on Twitter 13614314893264076807Twitter 1361431489326407680
Retweet on TwitterHealthNewsReview.org Retweeted
RxISKRxISK@RxISK·

A scary @statnews Op-Ed warns that govt attempts to rein in Pharma may cut off access to "life-changing" drugs.

It takes @garyschwitzer to let us know: the author spent 10 years as Pfizer's public-policy chief. https://twitter.com/garyschwitzer/status/1360325022578053123

Reply on Twitter 1361420459284131843Retweet on Twitter 13614204592841318437Like on Twitter 136142045928413184314Twitter 1361420459284131843
HealthNewsRevuHealthNewsReview.org@HealthNewsRevu·

.@TranspariMED criticizes STAT op-ed for not disclosing pharma funding of author’s institute - similar to criticism we’ve made of STAT op-eds in the past. @transparify @ThinkTankWatch @icer_review https://www.healthnewsreview.org/2021/02/transparency-watchdog-criticizes-stats-non-disclosure-on-pro-pharma-op-ed/

Reply on Twitter 1360214949704982532Retweet on Twitter 13602149497049825323Like on Twitter 13602149497049825328Twitter 1360214949704982532
View More

Categories

View More

Tags